This article was originally published by S.D. Wells at Natural News.
The depopulation machine is still in full gear, folks. The freaks in their white lab coats are still designing new plandemics with new deadly diseases and clot shots to go with it. Here’s the latest scoop.
A new peer-reviewed study published June 18, 2025, in Pathogens has revealed that scientists funded by the U.S. National Institutes of Health (NIH) have genetically engineered novel hybrid influenza viruses combining bat and human virus components. The research, conducted at the University of Missouri and partially funded by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), raises significant public health and biosecurity concerns.
-
- NIH-Funded Creation of Hybrid Bat-Human Influenza Viruses: Researchers at the University of Missouri, funded by NIH and CEIRR grants, engineered chimeric influenza viruses by combining bat virus genes with human H1N1 components—raising significant concerns due to their ability to replicate in mammalian cells and resist common antivirals.
-
- Engineered for Antiviral Resistance and Survival: The viruses were deliberately mutated at key sites (e.g., N31, H37, W41) to confer resistance to amantadine, a standard flu treatment, and to study how these mutations affect viral replication and survival, confirming the study’s gain-of-function nature.
-
- Pandemic Potential and Biosecurity Fears: Constructed using reverse genetics, these lab-created viruses could potentially infect humans, making them highly controversial in light of past pandemic origins linked to lab-based virus manipulation and prompting renewed biosecurity concerns.
-
- S. Taxpayer-Funded and Internationally Overseen: Despite growing public and governmental scrutiny, this research received funding from U.S. agencies including NIH/NIAID and CEIRR, with involvement from WHO-affiliated scientists and formal biosafety clearance—further fueling debate over accountability and transparency in high-risk virology.
NIH-funded researchers engineer drug-resistant bat-human hybrid influenza viruses in Missouri
Led by Dr. Richard Webby of St. Jude Children’s Research Hospital—also a World Health Organization collaborator—the study involved the creation of chimeric influenza viruses using a method known as reverse genetics. Researchers used internal genes from bat influenza viruses (H17N10 and H18N11) and combined them with surface proteins from the human H1N1 strain A/Puerto Rico/8/1934. These synthetic combinations were shown to replicate efficiently in mammalian cells, particularly Madin-Darby canine kidney (MDCK) cells, which are standard for studying influenza infectivity.
Crucially, the viruses were found to induce cytopathic effects (CPEs)—cellular damage caused by viral infection—suggesting they are functionally infectious in mammalian systems. This suggests a potential zoonotic crossover risk, where viruses engineered in the lab might be capable of jumping from animals to humans.
Even more concerning is the fact that the engineered viruses were resistant to the antiviral drug amantadine. The M2 protein of the bat influenza strains contained a naturally occurring N31 mutation known to confer resistance. Researchers further modified the M2 protein at key sites—such as H37, W41, and L36—to investigate the impact on viral replication, infectivity, and drug resistance. Several of these engineered variants survived and replicated successfully, revealing that small genetic changes could significantly enhance the virus’s survival and potential pathogenicity.
This kind of experimentation is considered gain-of-function (GoF) research—where viruses are intentionally altered to study how mutations affect traits like transmission, virulence, and immune evasion. While such studies aim to prepare for future pandemics, they are highly controversial due to the inherent risks of accidental or intentional release.
The study emphasized that reverse genetics was used to synthetically construct these novel viruses. Eight plasmids encoding the viral genome were mixed and incubated to generate recombinant strains—none of which exist naturally in the wild. This synthetic approach enables the creation of viruses with entirely new properties, increasing concerns about laboratory safety and global health implications.
This research comes at a time of heightened sensitivity to lab-origin theories of pandemics. Major U.S. intelligence agencies, including the FBI and CIA, have acknowledged that a laboratory-related incident is a plausible explanation for the origin of COVID-19. The creation of drug-resistant, mammalian-infectious viruses under U.S. government funding—without full transparency—has drawn criticism from biosecurity experts.
The project received approval from the University of Missouri’s Institutional Biosafety Committee (Protocol #12100) and was supported by the NIH, the Centers of Excellence in Influenza Research and Response (CEIRR), and university startup funds.
As debate grows over the ethics and safety of gain-of-function research, this study underscores the urgent need for stricter oversight, greater transparency, and reevaluation of federally funded virological experiments with pandemic potential. Bookmark Infections.news to get the latest updates about the engineered “bird flu pandemic” and the drug-resistant bat-human hybrid flu coming to fake news theatres near you!
Read the full article here
